Show simple item record

dc.contributor.authorSheikh, Hamid Y
dc.contributor.authorValle, Juan W
dc.contributor.authorPalmer, Karen
dc.contributor.authorSjursen, Ann-Marie
dc.contributor.authorCraven, Olive
dc.contributor.authorWilson, Gregory
dc.contributor.authorSwindell, Ric
dc.contributor.authorSaunders, Mark P
dc.date.accessioned2009-06-30T12:23:08Z
dc.date.available2009-06-30T12:23:08Z
dc.date.issued2007-01-15
dc.identifier.citationConcurrent irinotecan, oxaliplatin and UFT in first-line treatment of metastatic colorectal cancer: a phase I study. 2007, 96 (1):38-43 Br. J. Canceren
dc.identifier.issn0007-0920
dc.identifier.pmid17213824
dc.identifier.doi10.1038/sj.bjc.6603521
dc.identifier.urihttp://hdl.handle.net/10541/71937
dc.description.abstractThe feasibility of combining UFT plus leucovorin (LV) with alternating irinotecan and oxaliplatin was investigated in the first-line treatment of patients with advanced colorectal cancer. Twenty-five patients, median age 63 (range 24-79) years, World Health Organisation performance status 0-2 and median four marker lesions, received irinotecan 180 mg m(-2) on day 1, oxaliplatin 85-100 mg m(-2) on day 15 and UFT 200-300 mg m(-2) day(-1) with LV 90 mg day(-1), days 1-21 of a 28-day cycle. Patients were treated in cohorts of three. At the highest dose (irinotecan 180 mg m(-2), oxaliplatin 100 mg m(-2) and UFT 300 mg m(-2) day(-1)), three of four patients experienced grade 3 toxicity. Diarrhoea, lethargy and vomiting were dose-limiting. Three of nine patients had grade 2 toxicities at the maximum tolerated dose (irinotecan 180 mg m(-2), oxaliplatin 100 mg m(-2) and UFT 250 mg m(-2) day(-1)). There were no grade 3 toxicities in the first month of therapy. The overall response rate was 71% in 21 evaluable patients; progression-free survival was 8.8 months. Alternating irinotecan and oxaliplatin plus UFT is an effective and well-tolerated first-line treatment for patients with advanced colorectal cancer. We recommend a dose of irinotecan 180 mg m(-2) on day 1, oxaliplatin 100 mg m(-2) on day 15 and UFT 250 mg m(-2) day(-1) with LV 90 mg day(-1) on days 1-21 of a 28-day cycle for future studies.
dc.language.isoenen
dc.subjectColorectal Canceren
dc.subject.meshAdministration, Oral
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols
dc.subject.meshCamptothecin
dc.subject.meshChemotherapy, Adjuvant
dc.subject.meshCohort Studies
dc.subject.meshColorectal Neoplasms
dc.subject.meshDisease Progression
dc.subject.meshDose-Response Relationship, Drug
dc.subject.meshDrug Administration Schedule
dc.subject.meshDrug Combinations
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshInfusions, Intravenous
dc.subject.meshLeucovorin
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshOrganoplatinum Compounds
dc.subject.meshSurvival Rate
dc.subject.meshTegafur
dc.subject.meshTreatment Outcome
dc.subject.meshUracil
dc.titleConcurrent irinotecan, oxaliplatin and UFT in first-line treatment of metastatic colorectal cancer: a phase I study.en
dc.typeArticleen
dc.contributor.departmentDepartment of Clinical Oncology, Christie Hospital NHS Trust, Manchester M20 4BX, UK.en
dc.identifier.journalBritish Journal of Canceren
html.description.abstractThe feasibility of combining UFT plus leucovorin (LV) with alternating irinotecan and oxaliplatin was investigated in the first-line treatment of patients with advanced colorectal cancer. Twenty-five patients, median age 63 (range 24-79) years, World Health Organisation performance status 0-2 and median four marker lesions, received irinotecan 180 mg m(-2) on day 1, oxaliplatin 85-100 mg m(-2) on day 15 and UFT 200-300 mg m(-2) day(-1) with LV 90 mg day(-1), days 1-21 of a 28-day cycle. Patients were treated in cohorts of three. At the highest dose (irinotecan 180 mg m(-2), oxaliplatin 100 mg m(-2) and UFT 300 mg m(-2) day(-1)), three of four patients experienced grade 3 toxicity. Diarrhoea, lethargy and vomiting were dose-limiting. Three of nine patients had grade 2 toxicities at the maximum tolerated dose (irinotecan 180 mg m(-2), oxaliplatin 100 mg m(-2) and UFT 250 mg m(-2) day(-1)). There were no grade 3 toxicities in the first month of therapy. The overall response rate was 71% in 21 evaluable patients; progression-free survival was 8.8 months. Alternating irinotecan and oxaliplatin plus UFT is an effective and well-tolerated first-line treatment for patients with advanced colorectal cancer. We recommend a dose of irinotecan 180 mg m(-2) on day 1, oxaliplatin 100 mg m(-2) on day 15 and UFT 250 mg m(-2) day(-1) with LV 90 mg day(-1) on days 1-21 of a 28-day cycle for future studies.


This item appears in the following Collection(s)

Show simple item record